Search

Author/Creator Tomasello, G

1. 688PCorrelation between clinic-pathological features, MSI, PD-L1 and survival in resectable gastric cancer: Looking for prognostic biomarkers. (23rd October 2018)

Authors:
Ratti, M; Valeri, N; Hahne, J C; Lampis, A; Ghidini, M; Tomasello, G; Tanzi, G; Toppo, L; Pizzo, C; Donida, B; Senti, C; Salati, M; Trombatore, M; Fassan, M; Passalacqua, R
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 776TiPGlobal phase III study of tislelizumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (HCC): A trial-in-progress. (23rd October 2018)

Authors:
Qin, S; Finn, R S; Kudo, M; Meyer, T; Vogel, A; Ducreux, M P; Macarulla, T M; Tomasello, G; Boisserie, F; Hou, J; Li, C; Song, J; Zhu, A X
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial. Issue 12 (December 2022)

Authors:
Del Mastro, Lucia; Poggio, Francesca; Blondeaux, Eva; De Placido, Sabino; Giuliano, Mario; Forestieri, Valeria; De Laurentiis, Michelino; Gravina, Adriano; Bisagni, Giancarlo; Rimanti, Anita; Turletti, Anna; Nisticò, Cecilia; Vaccaro, Angela; Cognetti, Francesco; Fabi, Alessandra; Gasparro, Simon...
Journal:
Lancet oncology
Issue:
Volume 23:Issue 12(2022)
Page Start:
1571
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. LBA22Negative hyper-selection of RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients randomized to first-line FOLFOX plus panitumumab (Pan) followed by maintenance therapy with either 5FU/LV plus pan or single-agent pan: Translational analyses of the VALENTINO study. (23rd October 2018)

Authors:
Morano, F; Corallo, S; Di Bartolomeo, M; Lonardi, S; Cremolini, C; Rimassa, L; Sartore Bianchi, A; Murialdo, R; Zaniboni, A; Adamo, V; Tomasello, G; Tampellini, M; Fanchini, L; Schirripa, M; Clavarezza, M; Petrelli, F; Longarini, R; Cinieri, S; de Braud, F G M; Pietrantonio, F
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. O-013Impact of age and gender on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: a pooled analysis of TRIBE and TRIBE2 studies. (2nd July 2019)

Authors:
Zucchelli, G; Marmorino, F; Rossini, D; Aprile, G; Casagrande, M; Lonardi, S; Murgioni, S; Dell'Aquila, E; Tomasello, G; Moretto, R; Antoniotti, C; Borelli, B; Urbano, F; Ronzoni, M; Zaniboni, A; Manglaviti, S; Buonadonna, A; Ritorto, G; Masi, G; Allegrini, G
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 4
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. O-016First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study. (20th June 2018)

Authors:
Pietrantonio, F; Morano, F; Corallo, S; Raimondi, A; Loupakis, F; Cremolini, C; Smiroldo, V; Berenato, R; Bianchi, A Sartore; Tampellini, M; Bustreo, S; Clavarezza, M; Murialdo, R; Zaniboni, A; Tomasello, G; Peverelli, G; Antoniotti, C; Procaccio, L; Cinieri, S; Antonuzzo, L
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 5
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. O-016First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study. (20th June 2018)

Authors:
Pietrantonio, F; Morano, F; Corallo, S; Raimondi, A; Loupakis, F; Cremolini, C; Smiroldo, V; Berenato, R; Bianchi, A Sartore; Tampellini, M; Bustreo, S; Clavarezza, M; Murialdo, R; Zaniboni, A; Tomasello, G; Peverelli, G; Antoniotti, C; Procaccio, L; Cinieri, S; Antonuzzo, L
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 5
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. O-025A randomized, multicenter, phase 2 trial comparing CAPTEM versus FOLFIRI as second-line treatment for MGMT-methylated, RAS-mutated metastatic colorectal cancer patients. (2nd July 2019)

Authors:
Pietrantonio, F; Lobefaro, R; Antista, M; Miceli, R; Raimondi, A; Lonardi, S; Rimassa, L; Saggio, S; Capone, I; Farina, G; Longarini, R; Mosconi, S; Bianchi, A Sartore; Tomasello, G; Petrelli, F; Murgioni, S; Perrone, F; Barault, L; Milione, M; Nicolantonio, F Di
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 4
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. P-182Efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma in a phase 3, randomized, open-label, multicenter study - Trial in progress. (20th June 2018)

Authors:
Qin, S; Finn, R; Kudo, M; Meyer, T; Vogel, A; Ducreux, M; Macarulla, T; Tomasello, G; Boisserie, F; Hou, J; Li, C; Song, J; Zhu, A
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 5
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗